We previously reported baseline data from AYAC and non-cancer controls enrolled in the Adolescent and Young Adult Cancer Patients: Cognitive Toxicity on Survivorship (ACTS) study, as well as associations between BDNF with cognition from six months post-baseline [2, 14]. The gene discussed is BDNF; the disease is cancer.